FDA granted Fast Track designation to PDS0101 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.
Blue Note Therapeutics and OncoHealth have partnered to deliver oncology-specific mental health care.
C2i Genomics and Karkinos Healthcare have partnered to co-develop the minimal residual disease market in India.
Ultima Genomics is developing a high-throughput, low-cost sequencing platform that delivers $100 genome sequencing. Ultima has secured approximately $600 million in backing.
The National Cancer Institute approved the following clinical research studies last month.
In a letter addressed to FDA Commissioner Robert Califf, Republican leaders of the House Committee on Energy and Commerce and two of its subcommittees raised questions about the increasing number of clinical trials conducted in China by companies seeking FDA approval for “me-too” checkpoint inhibitor drugs.
In testimony before the House Labor HHS Appropriations Subcommittee May 26, cancer organizations recommended FY23 appropriations of $49 billion for NIH, $7.76 billion for NCI, and $426.6 million for the CDC’s Division of Cancer Prevention and Control.
Koen van Besien was named chief of the Division of Hematology and director of the Wesley Center for Immunotherapy at the University Hospitals Seidman Cancer Center in Cleveland.
Xiao-Jing Wang was named chief science officer at UC Davis Comprehensive Cancer Center.
The National Comprehensive Cancer Network announced the recipients of its 2022 awards.
